[ad_1] With an estimated $8 billion opportunity in the coming years, India is well-positioned to expand its global footprint in the CDMO sector. However, capturing a larger market share will require substantial infrastructure, talent, and compliance investments. In this special edition of Market Master, Madhu Kela, Founder of MK Ventures, discusses India’s CDMO potential with […]
US tariffs on Indian pharma will be hard to implement & inflationary: Systematix’s Vishal Manchanda – CNBC TV18
[ad_1] The United States may find it difficult to impose tariffs on Indian pharmaceutical products as it would likely drive up costs and contribute to inflation, according to Vishal Manchanda, Pharma Analyst at Systematix Group. Manchanda explained that Indian pharma companies operate on lower manufacturing costs compared to the US, and any tariffs would make […]
US FDA concludes inspection of Biocon Biologics’ Insulins Facility in Malaysia – CNBC TV18
[ad_1] Biocon Biologics announced on Saturday, September 28, that the US Food and Drug Administration (US FDA) has completed a Current Good Manufacturing Practice (cGMP) inspection of its Insulins Manufacturing Facility in Johor Bahru, Malaysia. The inspection, which took place between September 17 and September 27, 2024, covered multiple biologics manufacturing units and quality control […]
CNBC-TV18 accesses USFDA observations for Biocon Biologics unit. Details here – CNBC TV18
[ad_1] CNBC-TV18 has accessed the observations that the US Food & Drug Administration (USFDA) has issued to Biocon Biologics’ Units. The facility was inspected by the regulator between July 15 – July 19, and July 22 – July 26, post which, the observations were issued along with the form-483. Observations issued by USFDA: – Procedures […]